Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis | Synapse

May 6, 2020Open Access

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis. (Funded by NovImmune and the European Commission; NI-0501-04 and NI-0501-05 ClinicalTrials.gov numbers, NCT01818492 and NCT02069899.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Locatelli et al. (Wed,) studied this question.

synapsesocial.com/papers/69d790061f14cb2b27b8a3d1 https://doi.org/https://doi.org/10.1056/nejmoa1911326

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection2012 · 188 citations
2P156 Investigating the novel mechanism of action for NI-0501, a human interferon gamma monoclonal antibody2012 · 19 citations
3Incidence in Sweden and Clinical Features of Familial Hemophagocytic Lymphohistiocytosis1991 · 451 citations
4Infections in IFNGR-1-Deficient Children1997 · 75 citations
5Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome2017 · 120 citations